Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The myxobacterial antibiotic myxovalargin: Biosynthesis, structural revision, total synthesis and molecular characterization of ribosomal inhibition.
J. Am. Chem. Soc. 145, 851-863 (2023)
Resistance of bacterial pathogens against antibiotics is declared by WHO as a major global health threat. As novel antibacterial agents are urgently needed, we re-assessed the broad-spectrum myxobacterial antibiotic myxovalargin and found it to be extremely potent against Mycobacterium tuberculosis. To ensure compound supply for further development, we studied myxovalargin biosynthesis in detail enabling production via fermentation of a native producer. Feeding experiments as well as functional genomics analysis suggested a structural revision, which was eventually corroborated by the development of a concise total synthesis. The ribosome was identified as the molecular target based on resistant mutant sequencing, and a cryo-EM structure revealed that myxovalargin binds within and completely occludes the exit tunnel, consistent with a mode of action to arrest translation during a late stage of translation initiation. These studies open avenues for structure-based scaffold improvement toward development as an antibacterial agent.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Beam-induced Motion; Cryo-em Structure; Antimicrobial Peptide; Mechanism; Discovery; Defocus; Family
ISSN (print) / ISBN
0002-7863
e-ISSN
1520-5126
Zeitschrift
Journal of the American Chemical Society
Quellenangaben
Band: 145,
Heft: 2,
Seiten: 851-863
Verlag
American Chemical Society (ACS)
Verlagsort
1155 16th St, Nw, Washington, Dc 20036 Usa
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Medicinal Chemistry (IMC)
Förderungen
Bill and Melinda Gates Foundation
Deutsche Forschungsgemeinschaft (DFG)
MEYS CR
iNEXT
Intramural Research Program of NIAID/NIH
National Research Foundation of South Africa
South African Medical Research Council
Bill & Melinda Gates Foundation
Deutsche Forschungsgemeinschaft (DFG)
MEYS CR
iNEXT
Intramural Research Program of NIAID/NIH
National Research Foundation of South Africa
South African Medical Research Council
Bill & Melinda Gates Foundation